BidaskClub downgraded shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research report report published on Tuesday.

SUPN has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating and set a $49.00 target price on the stock in a report on Thursday, July 13th. Jefferies Group LLC set a $35.00 target price on shares of Supernus Pharmaceuticals and gave the company a buy rating in a report on Wednesday, May 10th. Stifel Nicolaus restated a buy rating and set a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Cantor Fitzgerald restated an overweight rating and set a $31.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, April 7th. Finally, Piper Jaffray Companies cut shares of Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $46.00 target price on the stock. in a report on Monday, July 17th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $46.14.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down 0.24% on Tuesday, reaching $41.00. 579,942 shares of the company traded hands. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $44.95. The stock’s 50 day moving average price is $42.17 and its 200-day moving average price is $32.99. The stock has a market capitalization of $2.06 billion, a P/E ratio of 22.05 and a beta of 1.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a net margin of 42.46% and a return on equity of 31.79%. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.91 million. Equities analysts forecast that Supernus Pharmaceuticals will post $1.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-nasdaqsupn-lowered-to-buy-at-bidaskclub/1461494.html.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 10,000 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $39.86, for a total value of $398,600.00. Following the completion of the transaction, the vice president now owns 27,500 shares of the company’s stock, valued at approximately $1,096,150. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the completion of the transaction, the vice president now directly owns 43,887 shares of the company’s stock, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. In the last three months, insiders sold 24,291 shares of company stock valued at $962,766. 6.70% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of SUPN. Meeder Asset Management Inc. raised its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth $127,000. Fortaleza Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth $160,000. State of Alaska Department of Revenue raised its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares during the period. Finally, OppenheimerFunds Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth $205,000. 90.97% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.